In preparation of a prospective multicentric collection of molecular prostate cancer data including PTEN immunohistochemistry, a ring trial was conducted to determine the status quo of the diagnostic accuracy of PTEN immunohistochemistry in localized low- to intermediate-risk prostate cancer among ten eminent university pathology institutes in Germany. This evidence concerns the gene PTEN and prostate carcinoma.